STATUS OF ASSESSMENTS
The table below lists the status of prioritized health technologies for HTA. Prioritized topics refer to health technologies that adhered to HTAC’s standard set of criteria responding to the priority health care needs of the country.
Definitions of each status:
- Assessment refers to the application of formal scientific methods of evidence synthesis to assess the clinical, economic, health system, ethical, legal and social impact of covering or disinvesting a particular health technology in the local Philippine context.
- Initial findings of the Assessment for Public Consultation refers to the key findings of the Assessment, which will be available for public consultation.
- Preliminary Recommendation refers to the initial recommendation issued by HTAC through a deliberative process of assessing the quality and the strength of the evidence guided by a decision framework aligned with the UHC law. Preliminary recommendation is made based on the results of the Assessment, and the inputs of stakeholders during the public consultation. After its release, the preliminary recommendation shall be open for appeals. Appeals refers to the process where all stakeholders are allowed to submit any comments, appeals, or requests for reconsideration within 10 working days based on any of the following grounds:
-
- Not all relevant evidence has been considered by HTAC
- New additional evidence that could influence the recommendation of HTAC
- A new price offer from the manufacturer of the product to ensure its affordability to DOH and PHIC.
-
- Final Recommendation refers to the recommendation by HTAC upon consideration of appeals on a particular health technology.
- Decision refers to the process of decision-making based on transmitted recommendation of the HTAC to the Secretary of Health and the PHIC Board of Directors for health interventions that are within their remit. The Secretary of Health and the PHIC Board of Directors shall provide an issuance in response to the transmitted recommendation of HTAC.
Note: In the event of a declared Public Health Emergency (e.g., COVID-19), status of health technologies (i.e., those that potentially respond to the said health emergency) will only be Assessment, Recommendation, and Decision. The Philippine HTA Process Guide elaborates both HTA processes during normal circumstances and during Public Health Emergencies.
Table of PUBLISHED Assessments
Name of health technology | Type of health technology | Assessment Status | Recommendation Status | Decision Status | Date of Publication |
---|---|---|---|---|---|
insulin glargine and insulin detemir for type 1 and type 2 diabetes mellitus | Drugs | Complete | Complete | Available | 03 October 2022 |
CoronaVac COVID-19 Vaccine for children 6 to 17 years old | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 05 October 2022 |
effectiveness andsafety of pazopanib in the managementof metastatic soft tissue sarcomapost-chemotherapy | Drugs | Complete | Complete | Available | 23 February 2021 |
eribulin in thetreatment of soft tissue sarcoma patientswith previous treatment of two otherchemotherapeutic agents for metastaticdisease | Drugs | Complete | Complete | Available | 13 June 2022 |
Lapatinib intreatment of HER2-positive breast cancerpatients | Drugs | Complete | Complete | Available | 31 May 2022 |
Rituximab for the Treatment of Non-Hodgkin’s Lymphoma | Drugs | Complete | Complete | Available | 29 July 2022 |
Second Booster of COVID-19 vaccines for the prevention of COVID-19 among individuals aged 50 years old and older and individuals with comorbidities aged 18 to 49 years old | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 23 August 2022 |
Use of Self-Administered Antigen Testing for COVID-19 | Clinical equipment and devices | Complete | Complete | Available | 07 April 2022 |
Fourth dose of COVID-19 Vaccines among the immunocompromised population (ICPs) | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 21 April 2022 |
tocilizumab for the treatment of COVID-19 | Drugs | Complete | Complete | Available | 11 May 2022 |
Potassium Citrate [1620 mg (15mEq)] tablet | Drugs | Complete | Complete | Available | 11 May 2022 |
Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years Old | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 11 February 2022 |
Emtricitabine + Tenofovir DisoproxilFumarate fixed-dose combination as OralPre-Exposure Prophylaxis (PrEP) toreduce the risk of sexually acquired HIVinfection | Drugs | Complete | Complete | Available | 17 December 2021 |
Vasopressin 20 I.U./mL (I.V./I.M./S.C.) | Drugs | Complete | Complete | Available | 02 March 2022 |
Sambong 250mg tablet for anti-urolithiasis (kidney stones) | Other Health Technologies | Complete | Complete | Available | 14 January 2022 |
Booster and Additional Dose Vaccination for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 03 November 2021 |
Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the prevention of COVID-19(December Reassessment) | Vaccines, Preventive and promotive health services | Complete | Complete | Available | December 14, 2021 |
Covovax for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | December 14, 2021 |
Whole Virion, Inactivated Corona Virus [Covaxin] for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | November 29, 2021 |
COVID-19 Vaccine Sinopharm for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | November 29, 2021 |
Two-dose Inactivated Polio Vaccine (IPV) versus One-dose IPV for the prevention of Poliomyelitis | Vaccines, Preventive and promotive health services | Complete | Complete | Available | July 13, 2021 |
Use of casirivimab+imdevimab for the treatment of COVID-19 | Drugs | Complete | Complete | Available | 24 December 2021 |
Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV | Drugs | Complete | Complete | Available | August 24, 2021 |
RapidAntigen Test Kits for the Diagnosis ofCOVID-19 (September 2021 Updates) | Clinical equipment and devices | Complete | Complete | Available | 27 September 2021 |
Use of RT-PCR Testing for COVID-19 (April 2021 Reassessment) | Clinical equipment and devices | Complete | Complete | Available | 30 April 2021 |
SARS-CoV-2Vaccine (Vero Cell), Inactivated[CoronaVac] for the prevention ofCOVID-19 (July Updates) | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 30 July 2021 |
Sputnik V, Pfizer - BioNTech, Janssen, AstraZeneca(June Reassessments) | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 25 June 2021 |
Rapid antibody tests (RATs)(May 2020 reassessment) | Clinical equipment and devices | Complete | Complete | Available | 01 August 2020 |
Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) | Clinical equipment and devices | Complete | Complete | Available | 18 May 2020 |
AMTI uAI-Discover-PNA | Clinical equipment and devices | Complete | Complete | Available | 14 April 2020 |
Favipiravir | Drugs | Complete | Complete | Available | 08 April 2020 |
Cycloferon | Drugs | Complete | Complete | Available | 07 April 2020 |
Huawei Cloud AI-Assisted Diagnosis | Clinical equipment and devices | Complete | Complete | Available | 13 April 2020 |
Rapid antibody tests (RATs)(March 2020 assessment) | Clinical equipment and devices | Complete | Complete | Available | 25 March 2020 |
Use of Pooled Testing for the screening and surveillance of COVID-19 | Clinical equipment and devices | Complete | Complete | Available | 28 October 2020 |
Use of Rapid Antigen test kits for the diagnosis of COVID-19 | Clinical equipment and devices | Complete | Complete | Available | 02 October 2020 |
Extracorporeal Membrane Oxygenation (ECMO) for COVID-19 patients with ARDS | Clinical equipment and devices, Medical and surgical procedures | Complete | Complete | Available | 10 September 2020 |
COVID-19 MRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 28 May 2021 |
High-Flow Nasal Cannula Oxygen Therapy for the treatment of Acute Hypoxemic Respiratory Failure for COVID-19 | Clinical equipment and devices, Medical and surgical procedures | Complete | Complete | Available | 01 December 2020 |
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 08 February 2021 |
SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 09 April 2021 |
Sputnik V Gam-COVID-Vac COVID-19 Vaccine | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 12 April 2021 |
BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available | 02 February 2021 |
Pneumococcal Conjugate Vaccine 13 (PCV-13)(2020 Reassessment) | Vaccines | Complete | Complete | Available | 01 July 2020 |
Janssen Ad26.COV2.S (COVID-19) Vaccine for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete |